Characteristics of a highly labile human type 5 17beta-hydroxysteroid dehydrogenase
about
Characterization of 17alpha-hydroxysteroid dehydrogenase activity (17alpha-HSD) and its involvement in the biosynthesis of epitestosteroneAldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancerA novel polymorphism in the 17beta-hydroxysteroid dehydrogenase type 5 (aldo-keto reductase 1C3) gene is associated with lower serum testosterone levels in caucasian menType 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) contributes to testosterone production in the adrenal reticularisTissue distribution of human AKR1C3 and rat homolog in the adult genitourinary systemHuman 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormonesThe molecular biology, biochemistry, and physiology of human steroidogenesis and its disordersKLF15 Is a transcriptional regulator of the human 17beta-hydroxysteroid dehydrogenase type 5 gene. A potential link between regulation of testosterone production and fat stores in womenExpression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinomaEmerging mechanisms of resistance to androgen receptor inhibitors in prostate cancerSteroidogenesis in the skin: implications for local immune functionsBeyond T and DHT - novel steroid derivatives capable of wild type androgen receptor activationStructure of the human 3alpha-hydroxysteroid dehydrogenase type 3 in complex with testosterone and NADP at 1.25-A resolutionStructure-based inhibitor design for an enzyme that binds different steroids: a potent inhibitor for human type 5 17beta-hydroxysteroid dehydrogenaseCrystal Structures of Three Classes of Non-Steroidal Anti-Inflammatory Drugs in Complex with Aldo-Keto Reductase 1C3Characterization and localization of human type10 17beta-hydroxysteroid dehydrogenasePotential Antiosteoporotic Natural Product Lead Compounds That Inhibit 17β-Hydroxysteroid Dehydrogenase Type 2.Expression and localization of estrogenic type 12 17beta-hydroxysteroid dehydrogenase in the cynomolgus monkeyExpression of AKR1C3 in renal cell carcinoma, papillary urothelial carcinoma, and Wilms' tumor.Recent Advances in Drug Design and Drug Discovery for Androgen- Dependent Diseases.Estrogen and androgen-converting enzymes 17β-hydroxysteroid dehydrogenase and their involvement in cancer: with a special focus on 17β-hydroxysteroid dehydrogenase type 1, 2, and breast cancer.Elevated AKR1C3 expression promotes prostate cancer cell survival and prostate cell-mediated endothelial cell tube formation: implications for prostate cancer progression.Molecular characterization of a first human 3(alpha-->beta)-hydroxysteroid epimerase.Suppressed expression of type 2 3alpha/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) in endometrial hyperplasia and carcinoma.Variation in AKR1C3, which encodes the neuroactive steroid synthetic enzyme 3α-HSD type 2 (17β-HSD type 5), moderates the subjective effects of alcoholDevelopment of the human adrenal zona reticularis: morphometric and immunohistochemical studies from birth to adolescence.Human type 3 5α-reductase is expressed in peripheral tissues at higher levels than types 1 and 2 and its activity is potently inhibited by finasteride and dutasteride.Inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3): overview and structural insights.Testosterone, not 5α-dihydrotestosterone, stimulates LRH-1 leading to FSH-independent expression of Cyp19 and P450scc in granulosa cells.Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs.Identification of a functional polymorphism of the human type 5 17beta-hydroxysteroid dehydrogenase gene associated with polycystic ovary syndrome.Variation in genes encoding the neuroactive steroid synthetic enzymes 5α-reductase type 1 and 3α-reductase type 2 is associated with alcohol dependence.Prostaglandin (PG) F2 alpha synthesis in human subcutaneous and omental adipose tissue: modulation by inflammatory cytokines and role of the human aldose reductase AKR1B1.Evolution of retinoid and steroid signaling: vertebrate diversification from an amphioxus perspective.Adrenal androgens and androgen precursors-definition, synthesis, regulation and physiologic actions.Mechanisms mediating androgen receptor reactivation after castration.Role of aldo-keto reductase enzymes in mediating the timing of parturitionOverexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5α-reductase inhibitor finasteride.On the role of skin in the regulation of local and systemic steroidogenic activities.Nonreplication of the type 5 17beta-hydroxysteroid dehydrogenase gene association with polycystic ovary syndrome.
P2860
Q21284388-604257FD-8546-47D8-9C40-FF8BBDB349C2Q24293323-C3A9CB9D-BB11-4672-AE06-9E1EB9FF1B45Q24303944-F030D44B-61A3-418E-B4FC-3A0FDD7B9C39Q24311152-CAAE696E-3917-403E-BA40-F39CED68D09DQ24328776-4A53C10E-FFAD-422E-B632-C1A6E05B9D93Q24532164-4FCD22CD-C0A8-4FF6-B873-0EE695B2C4CDQ24613957-CBD2738B-9573-4ABA-82A2-1759F9942DFBQ24650529-56C839CF-319C-476D-B7B5-A748178CBD01Q24804238-11244FA4-AAE9-4E3C-B374-9B2A2E75AD05Q26777310-D409BB25-92D9-43FB-BED9-D473F8D33D17Q26830355-39896E98-15B6-494C-A0DA-25A726C7B376Q27007208-24FF61B7-62A1-4EBF-A80E-13B7606F2ACCQ27634265-FE844FC6-19ED-459E-B95B-8F8FBF58066BQ27643293-101411E0-079F-4E58-B5DC-DC15B924A86DQ27671816-97DB76C5-C472-4FA0-8CED-BCF43E630FC9Q28216369-E2D054FD-15D0-4263-B6C4-63CFB6582810Q30847424-6C9C89F9-5DEA-41F5-BAB1-16F02D1B55A0Q33272206-7C5DEEA9-93EF-48E3-AD0E-E3302174F571Q33604649-E97D2ED9-5152-419E-91F6-6B5A9EF589AFQ33623428-2A2865FB-73CE-409E-911C-378AE2180C38Q33728381-DC800ABF-C222-481C-AF37-7388E305259DQ33763973-B9985FA8-2C24-41C7-ADFB-0A56D342D1E9Q33909706-410552A2-A602-49C6-9E28-F0497D0C85CAQ34007469-A7EBC852-23AD-49CC-8D5A-B309E4AA90F9Q34054066-BCCA046B-82AA-4531-8070-423E5C75EE88Q34154923-A5DB7C25-1701-4964-B318-90ADBC6DF1D3Q34475888-787BD06A-47A7-4D83-A7EB-6897B7FCB924Q34618859-6298F8F2-9B5B-4C62-8C47-BE5C5F4DBF27Q34712155-898F43C5-731E-46C6-9847-D38C04BC1AF7Q34795526-19B5E093-9856-4B13-80AD-FAA0C472ED41Q34863558-E9C82105-310F-44A0-9E79-71BE7D5630B7Q34872888-89F362C4-B4B9-4823-ACD5-093C8781AA24Q35129193-84E9DCA2-43A0-4A2B-9334-F716DD9895A0Q35253224-DA909B68-7702-4B1C-A50F-0A83FD580B8EQ35624417-71F79CDD-5B9E-40C0-8938-B0BE195CA4FAQ35633454-EFF463D8-72AF-4921-A6C8-63998DB3D7F8Q35660367-EAE99CEC-0641-4AA0-BE16-B1D325772188Q35869909-86E1311A-35F2-46CA-BD8F-2B309992051CQ36244943-2C89B416-F8AB-45F1-944E-4D644CABE08AQ36360763-1A52E940-CE72-4F89-9B10-479A00F3F764
P2860
Characteristics of a highly labile human type 5 17beta-hydroxysteroid dehydrogenase
description
1999 nî lūn-bûn
@nan
1999 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Characteristics of a highly labile human type 5 17beta-hydroxysteroid dehydrogenase
@ast
Characteristics of a highly labile human type 5 17beta-hydroxysteroid dehydrogenase
@en
Characteristics of a highly labile human type 5 17beta-hydroxysteroid dehydrogenase
@nl
type
label
Characteristics of a highly labile human type 5 17beta-hydroxysteroid dehydrogenase
@ast
Characteristics of a highly labile human type 5 17beta-hydroxysteroid dehydrogenase
@en
Characteristics of a highly labile human type 5 17beta-hydroxysteroid dehydrogenase
@nl
prefLabel
Characteristics of a highly labile human type 5 17beta-hydroxysteroid dehydrogenase
@ast
Characteristics of a highly labile human type 5 17beta-hydroxysteroid dehydrogenase
@en
Characteristics of a highly labile human type 5 17beta-hydroxysteroid dehydrogenase
@nl
P2093
P356
P1433
P1476
Characteristics of a highly labile human type 5 17beta-hydroxysteroid dehydrogenase
@en
P2093
P304
P356
10.1210/EN.140.2.568
P407
P577
1999-02-01T00:00:00Z